A Phase 3 interventional study of 180mg of ETC-1002(bempedoic acid) and Placebo in Hyper-low-density Lipoprotein (LDL) Cholesterolemia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to confirm the superiority of ETC-1002 after 12 weeks of administration at 180 mg/day to placebo in patients with hyper-LDL cholesterolemia who have inadequate control of low-density lipoprotein cholesterol (LDL C).
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with liver disease or dysfunction, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 180mg of ETC-1002(bempedoic acid)
Drug: Placebo
180mg, tablet, once daily, for 12 weeks
placebo, tablet, once daily, for 12 weeks
Percent Change in LDL-C From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1.
Time frame: Baseline, week12
Percent Change in Non-HDL Cholesterol From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Total Cholesterol From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Apolipoprotein B From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Hemoglobin A1c From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12
The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.
Time frame: Baseline, week12
| Milestone | ETC-1002 180 mg | Placebo |
|---|---|---|
| Started | 48 | 48 |
| Completed | 46 | 45 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1.
| Percent Change | ETC-1002 180 mg | Placebo |
|---|---|---|
| Percent Change in LDL-C From Baseline to Week 12 | -25.25 ± 1.864 | -3.46 ± 1.901 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 180 mg | Placebo |
|---|---|---|
| Percent Change in Non-HDL Cholesterol From Baseline to Week 12 | -20.33 ± 1.704 | -2.76 ± 1.720 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 180 mg | Placebo |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Week 12 | -16.36 ± 1.405 | -2.23 ± 1.409 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 180 mg | Placebo |
|---|---|---|
| Percent Change in Apolipoprotein B From Baseline to Week 12 | -18.10 ± 1.762 | -0.67 ± 1.799 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 180 mg | Placebo |
|---|---|---|
| Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12 | 15.40 ± 65.246 | 119.60 ± 66.542 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 180 mg | Placebo |
|---|---|---|
| Percent Change in Hemoglobin A1c From Baseline to Week 12 | -0.87 ± 0.590 | 0.16 ± 0.594 |
The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.
| Participants | ETC-1002 180 mg | Placebo |
|---|---|---|
| Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12 | 30 | 4 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 28 (+7) days after the last dose of study medication, up to 21 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETC-1002 180 mg | 0/48 (0%) | 0/48 (0%) | 13/48 (27.1%) |
| Placebo | 0/48 (0%) | 0/48 (0%) | 6/48 (12.5%) |
| Event | ETC-1002 180 mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 7/48 | 5/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/48 | 0/48 |
| Back painMusculoskeletal and connective tissue disorders | 3/48 | 1/48 |
| Age, Categorical(Participants) | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 25 | 45 |
| >=65 years | 28 | 23 | 51 |
| Age, Continuous(years) | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|
| Mean | 64.6 ± 13.02 | 63.9 ± 12.98 | 64.2 ± 12.93 |
| Sex: Female, Male(Participants) | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|
| Female | 28 | 23 | 51 |
| Male | 20 | 25 | 45 |
| Race/Ethnicity, Customized(Participants) | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|
| Japanese | 48 | 48 | 96 |
| Region of Enrollment(participants) | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|
| Japan | 48 | 48 | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: "Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Feb 2023 to primary completion in Feb 2024, 12 months.
Results were first posted in Mar 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid
Otsuka Pharmaceutical Co., Ltd. →